Valencia Technologies is excited to announce that it has successfully raised $35,000,000 in its latest funding round, marking a major milestone in the advancement of neuromodulation technology for bladder dysfunction. Focused on transforming the standard of care, the company’s innovative platform centers around the eCoin®—a coin-sized, leadless neurostimulator that offers automatic and effective treatment for Urge Urinary Incontinence. Engineered to be radically small—just 1/8th the size of the smallest device currently on the market—the eCoin® is designed to improve quality of life for patients managing chronic conditions.
Guided by seasoned leader Jeff Greiner and brought to life by the visionary expertise of engineers Dave Peterson and Chula Thenuwara, Valencia Technologies builds on a foundation of scientific discovery and clinical innovation. The funding will accelerate key research and development initiatives, scale production capabilities, and expand market access, ensuring that the eCoin® reaches a broader patient base. This capital infusion strategically positions the company to fully leverage its robust technology platform, drawing on scientifically verifiable work in fields such as acupuncture and neuromodulation. Each step forward involves translating breakthrough research into real-world, effective treatments that address unmet medical needs in chronic conditions.
With a commitment to transforming healthcare, Valencia Technologies is poised to redefine therapeutic possibilities for bladder dysfunction. The company’s journey—from initial innovation to commercialization—reflects a steadfast dedication to improving patient outcomes and pushing the boundaries of advanced device therapy. For more insights into Valencia Technologies and details of their current initiatives, please visit our website at www.valenciatechnologies.com.
